−8.57 MILS
About NEXTGEN BIOMED LTD
Sector
CEO
Harel Moshe Hershtik
Headquarters
Raanana
Founded
1990
ISIN
IL0010839301
FIGI
BBG000BJNFW1
Nextgen Biomed Ltd. operates as a research and development company. Its primary product is Eyepen, a smart and modular device consisting of pens for injecting insulin, and helps users self-manage the treatment of diabetes by documenting the times and doses of taking insulin by injection. The company was founded on December 26, 1990 and is headquartered in Raanana, Israel.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of NXGN is 104.70 ILA — it has decreased by 1.97% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TASE exchange NEXTGEN BIOMED LTD stocks are traded under the ticker NXGN.
Yes, you can track NEXTGEN BIOMED LTD financials in yearly and quarterly reports right on TradingView.
Like other stocks, NXGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEXTGEN BIOMED LTD stock right from TradingView charts — choose your broker and connect to your account.